Culture of care in Laboratory Animal Science (LAS) refers to a commitment toward improving animal welfare, scientific quality, staff wellbeing, and transparency for all stakeholders, ensuring that the animals and personnel involved are treated with compassion and respect. A strong culture of care can be established by the proactive implementation of the Three Rs, sharing best practices, caring for and respecting animals and colleagues, empowering staff, taking responsibility for our actions, and having a caring leadership. Culture of care, when established, should be evaluated continuously, in order to foster its progress and persistence. Even though several tools for assessing the culture of care within an institution have been proposed, an ultimate standard for measuring the concept is lacking. Here, we review the culture of care concept and propose the ‘Capability Maturity Model’ as a means of quantifying culture of care in the laboratory animal setting.
Seven brands of veterinary rabies vaccines are commercially available in Sri Lanka, but there is no established procedure to test the potency of the vaccines at the local level, especially prior to their release. The aim of this study was to test the potency of these vaccines using a mouse challenge test in collaboration with the EU/WOAH/WHO Reference Laboratory for Rabies, ANSES-Nancy, France. Based on the European Pharmacopoeia, the inactivated rabies vaccines complied with the mouse potency test if the estimated potency is ≥1.0 IU in the smallest prescribed dose. Among the eight tested vaccines, four single-dose preparations (Rabisin™, Raksharab™, Nobivac™ RL, and Nobivac™ Rabies) were compliant, with potencies of 12 IU/dose, 7.2 IU/dose, 4.4 IU/dose, and 3.4 IU/dose, respectively. Three of the single-dose preparations (Canvac™ R, Defensor™ 3, and Rabies killed vaccine) were not compliant, with potency values <1.0 IU/dose. One multidose preparation (Raksharab™ multidose) had a potency of 1.3 IU/dose, even though the test was not validated. Based on these results, it appears that some rabies vaccine batches that are currently available in the local market do not comply with the mouse potency test. Testing the vaccines’ potency before registration and release to the market appears to be an important step to allow good immunization to animals during pre-exposure vaccination programs.
1 January 2023 in Clinical and Experimental Vaccine Research
Anti-rabies vaccines (ARVs) with good immunogenic capacity play an important role in controlling the deadly zoonotic rabies in Sri Lanka. The ARVs currently marketed in the country have not been tested for their efficacy and potency at the local level before being released to the market. This article outlines the proposed project formulated to determine the efficacy and potency of these ARVs in generating immunity against rabies. The authors propose that this project will be articulated in three main categories. Part I will be the immunogenicity measurement using, New Zealand White rabbits as the animal model. Part II will be a field study with a sample dog population, including domestic and free-roaming dogs and Part III will be the potency testing of the ARVs using the mouse challenge test. Immunogenicity will be assessed by measuring the humoral immunity development following vaccination, using the methods of Florescent Antibody Virus Neutralization (FAVN) and ELISA. The project will be conducted in collaboration with WHO/WOAH Reference Laboratory for Rabies in Nancy, France, and Medical Research Institute, Colombo 08, Sri Lanka.
1 January 2026 in Clinical and Experimental Vaccine Research
Several brands of anti-rabies vaccines (ARVs) are used for dog vaccination in Sri Lanka, which have shown major differences in their potency levels. This comparative study was conducted to determine humoral immune response of these ARVs using 2 different animal species. The reliability of an enzyme-linked immunosorbent assay (ELISA) antibody kit was assessed in comparison to the standard Fluorescent Antibody Virus Neutralization (FAVN) test. The laboratory animal study was conducted using 3–4 months old sero-negative New Zealand White rabbits. Nine vaccines from 7 producers were tested including 8 monovalent inactivated ARVs: Canvac R® single-dose and multi-dose, Nobivac® Rabies, Rabies Killed® Vaccine, Rabisin®, Defensor 3®, Raksharab® single-dose and multidose, and one bivalent inactivated ARV, Nobivac® RL. Second part was conducted in field dogs. Four vaccines with the highest potencies were selected for this field dog study. Animals were vaccinated subcutaneously with one dose of a selected ARV. Day 0 blood samples were collected just before the vaccination and Day 7, Day 14, and Day 30 samples from rabbits and Day 30 samples from dogs were collected post-vaccination. Significant differences of humoral immune response between different vaccines brands were observed in both animal species. The coefficient of concordance between the FAVN test and the ELISA was 54.6% and 85.3% for rabbits and dogs respectively. The overall results showed that ARVs with proven potency can induce a robust humoral immune response following vaccination. There was a comparatively higher agreement between the FAVN test and the ELISA.
30 September 2024 in INDIAN JOURNAL OF PHYSIOLOGY AND ALLIED SCIENCES
Rabies is a vaccine-preventable fatal viral disease, which affects both domestic and wild mammals. The main reservoir species of rabies in Sri Lanka is dogs. Elephants, being mammals, are also susceptible to rabies but, no detailed controlled study has been done concerning anti-rabies immunogenicity. This research project focuses on determining the pattern of immunogenicity in both routinely vaccinated and zero-positive Sri Lankan elephants following anti-rabies vaccination (ARV). 30 easily accessible elephants from the Pinnawala elephant orphanage will be used as the routinely vaccinated group of elephants. This group of elephants will be randomly allocated into two groups (n=15 elephants each) a year after the initial anti-rabies vaccination. Two previously unvaccinated calves will be selected as the zero-positive control group of the study, and they will be allocated into two groups (A, B). All elephants will be immunized using 1ml of ARV while elephants in zero positive control group B will be immunized using 2ml of ARV as the first dose. A blood sample will be collected before vaccination in all elephants. Post-vaccination blood samples will be collected on planned dates from the different study groups. Sample analysis of the study will be done by FAVN test and ELISA.